Lynn et al. developed m909-based CAR T cells for the treatment of acute myeloid leukemia, building on the success of the anti-FRβ antibody m909, as FRβ upregulation is observed in approximately 70% of AML cases [153]. The gene discussed is FOLR2; the disease is acute myeloid leukemia.